Purpose: The diagnosis of leptomeningeal metastases is usually confirmed by the finding of malignant cells by cytologic examination in the cerebrospinal fluid (CSF). More sensitive and specific cancer biomarkers may improve the detection of tumor cells in the CSF. Promoter methylation of the human telomerase reverse transcriptase (hTERT) gene characterizes most cancer cells. The aim of this study was to develop a sensitive method to detect hTERT methylation and to explore its use as a cancer biomarker in CSF.
Introduction
Leptomeningeal metastasis occurs in approximately 5% to 10% of patients with systemic cancer (1, 2) . Although almost any type of malignant disease can disseminate to the leptomeninges, leptomeningeal metastasis are mostly found in patients with hematologic malignancies and in solid tumors such as breast cancer, lung cancer, gastrointestinal cancer, and melanoma. The finding of malignant cells in the cerebrospinal fluid (CSF) is essential for the diagnosis of leptomeningeal metastasis, and is the only examination that directly verifies the presence of malignancy in CSF (3) . Because early treatment of leptomeningeal metastasis may prevent neurologic deterioration, it is important to establish the diagnosis as early as possible. For further diagnostic procedures and treatment modalities, it is necessary to determine whether the presence of malignant cells in the CSF is either the first manifestation of an unknown primary tumor or a metastatic complication of a known primary tumor. In patients treated for leptomeningeal metastasis, CSF examination could be useful in monitoring the response to therapy. Nevertheless, cytologic diagnosis is often difficult to establish by morphology alone, especially in cases with low numbers of cells (4) . It is also established that CSF is a poor medium for cell preservation in which neoplastic cells may present ambiguous morphologic features and thus may become difficult to identify. In addition, after intrathecal chemotherapy and/ or irradiation, some normal cells do develop abnormal morphology and may be mistakenly recorded as cancerous cells. For solid tumors, repeated CSF examinations may be required to establish the diagnosis of leptomeningeal metastasis. Because of a certain lack of accuracy in the cytologic diagnosis of CSF samples, there is an increasing interest in the development of new biomarkers.
Abnormal patterns of DNA methylation have been recognized in cancer cells. They exhibit both loss of methylation in the CpG-depleted regions and gain in methylation of CpG islands (5, 6) . Methylation of CpG islands in gene promoter regions is commonly associated with aberrant silencing of transcription and is a mechanism for inactivation of tumor-suppressor genes, in addition to mutation or deletion (7, 8) . Hypermethylation of genes has already been used to detect tumor cells, such as methylation of APC and human telomerase reverse transcriptase (hTERT) in esophageal cancers (9) , MGMT in glioblastoma (10) , and RASSF1A in breast cancers (11) .
Telomerase activity is detected in about 90% of human cancers, but not in the majority of normal cells. The expression of its catalytic subunit, hTERT, has been shown to be a biomarker in hepatocellular, colorectal, and esophageal carcinomas (12) (13) (14) . Activated lymphocytes, which infiltrate many tumor tissues, also express hTERT and have an active telomerase complex (15) . In body fluids, including CSF, proliferating lymphocytes can be the cause of hTERT expression (16) (17) (18) , which limits its use as a diagnostic tool in cancer. In contrast, hTERT promoter methylation is correlated with hTERT expression in most telomerase-positive tumors (19) (20) (21) (22) , whereas the promoter is unmethylated in telomerase-positive-activated lymphocytes (23) . Therefore, the use of hTERT methylation as a cancer biomarker might circumvent the confounding effect of activated lymphocytes.
The aim of this study was to develop a specific, sensitive, quantitative, and fast method for detection of low level of hTERT methylation and to explore its potential use as a cancer biomarker in the diagnosis of metastasis in CSF. As the number of tumor cells can vary, a method is needed with a detection level as low as 1% of methylated DNA in a nonmethylated background. In this study, we developed an approach, which combines real-time TaqMan PCR and realtime methylation-sensitive high-resolution melting (MS-HRM) analyses to determine low levels of hTERT methylation, which could be applicable to clinical samples.
Materials and Methods

Samples
All available 77 CSF specimens were collected from 67 patients seen at the Centre Hospitalier Universitaire Vaudois (Lausanne, Switzerland) and at regional hospitals between 2005 and 2010. All CSF samples were immediately processed for cytologic analysis (J. C. de Flaugergues and R. Janzer, Lausanne University Hospital, Lausanne, Switzerland). Residual CSF samples were 1 to 2 mL in volume and were stored at 4 C for 1 to 4 days before processing for hTERT methylation analysis. No patient had CSF especially for this study. Fifty-three CSF samples from 43 patients with a known malignancy were suspected for leptomeningeal metastasis. For all these patients, the primary tumor was also investigated for hTERT methylation analysis. In addition, 24 CSFs from 24 patients with non-neoplastic diseases (including inflammatory diseases and viral syndromes) were used as negative controls. The use of CSF samples and tumor tissues was done according to the guidelines of the local ethical committee.
Control samples
Hela DNA was used as hTERT-hypermethylated standard and DNA from placental tissue as hTERT-unmethylated standard. Combination of hypermethylated and unmethylated allele dilutions was created by mixing genomic DNAs before bisulfite modification to obtain methylated/ unmethylated hTERT template ratios of 0%, 1%, 10%, 20%, 50%, 80%, and 100%.
DNA Extraction and bisulfite modification
DNAs were extracted using the DNeasy Tissue Extraction Kit (Qiagen) with some modifications. Qiagen ATL buffer (360 mL) and 40 mL (600 ng) of proteinase K were added to 1 to 2 mL of CSF. After evaporation in a Speedvac to a residual volume of 400 mL, DNA extraction was conducted as recommended by the manufacturer. Bisulfite modification of the genomic DNA was conducted with the EpiTect Bisulfite Kit (Qiagen). The starting amount of DNA was 1 mg for the controls and tumor tissues, but variable amounts of CSF DNA (10-500 ng) were used depending on the number of cells contained in each sample.
hTERT Methylation analysis
Real-time MS-HRM, composed of both real-time TaqMan PCR and HRM analyses, was conducted. The TaqMan MGB probe was designed to contain 4 CpG sites that were found methylated in cancers (21, 24) . This probe was labeled with the yellow-fluorescent dye TET (tetrachloro fluorescein) and can only detect the methylated allele. PCR contained 2.5 mmol/L MgCl 2 , 250 mmol/L of deoxynucleotide triphosphate, 200 nmol/L of each primer, 200 nmol/L of labeled probe, 5 mmol/L SYTO 9 dye (Invitrogen), 5% dimethyl sulfoxide, 1 U Platinium Taq polymerase (Invitrogen), and 2 mL of bisulfite-modified DNA template. A 107-bp hTERT-bisulfite-modified fragment
Translational Relevance
Detection of aberrantly methylated promoter genes in cerebrospinal fluid (CSF) of patients with cancer provides an attractive strategy for noninvasive diagnosis of leptomeningeal metastasis. Our study identified an epigenetic biomarker that accurately detects tumor in CSF samples. Human telomerase reverse transcriptase (hTERT) methylation, characterizing most cancer cells, was found to be a sensitive and specific biomarker for leptomeningeal metastasis detection in CSF. The realtime PCR assay conducted in this study can be easily applied for routine screening of leptomeningeal metastasis in CSF samples. In clinical practice, the use of hTERT methylation, as a cancer biomarker, provides a useful contribution to the diagnosis of leptomeningeal metastasis, especially in cases where the cytologic diagnosis is suspicious but not conclusive for malignancy.
was amplified using the following primers: forward 5 0 -CCCCGCGTCCGAACCT-3 0 , reverse 5 0 -TTCGAGG-GAGGGGTTATGATGTG-3 0 , and labeled probe 5 0 -TET-CGACCAAAAAATCGCCGCACGCA-BHQ1-3 0 . PCR amplification and HRM analysis were carried out sequentially on a Rotor-Gene 6000 (Qiagen). The program of amplification consisted of 5 minutes at 95 C, followed by 40 cycles of 10 seconds at 95 C and 30 seconds at 60 C or 64 C. HRM analysis was conducted with temperature ramping from 70 to 95
C. The level of methylation was calculated as the ratio between methylation part (M) monitored by the TaqMan MGB probe and the totality of the PCR amplification (MþU) measured by the SYTO9. The ratio was calculated on the basis of the 2 standard curve relative quantification methods. The HRM curves were normalized by the software to allow comparison between the samples. All the samples were analyzed in duplicate.
Statistical analysis
Microsoft Excel was used for 2-tailed Student t test to evaluate the difference of methylation level between CSF samples.
Results
hTERT Methylation by real-time MS-HRM assay HRM was previously described as a specific method for methylation analysis (25) . HRM relies upon the precise monitoring of the change of fluorescence intensity as a DNA duplex melts. This technique allows a quality control to avoid false-positive results caused by incomplete conversion or false priming due to less stringent PCR conditions (26) . To induce a PCR bias toward the methylated templates, the sensitivity of the HRM was significantly increased by introducing CpG sites into the PCR primers (26) . Therefore, primers with a limited number of CpG sites, away from the 3 0 end (27), were selected. Moreover, to reduce potential false-positive or false-negative signals, hTERT methylation was simultaneously investigated by real-time TaqMan PCR and MS-HRM in a single-tube assay. This approach was termed "real-time MS-HRM". In this method, TaqMan assay covers methylation of 4 CpG sites by a fluorescent probe, and HRM scans all of the CpGs flanked by the primers binding to the target sequence, regardless of the methylation status of CpGs in the primer-binding side. The TaqMan probe had a high specificity and the background signal on unmethylated targets was negligible. In these conditions, it was possible to detect methylation of DNA mixtures containing 10% of methylation with high resolution (Fig.  1A) . Increasing of the annealing temperature of PCR amplification allowed higher sensitivity. At 64 C, samples containing 1% methylated template could be easily detected by MS-HRM and TaqMan analyses (Fig. 1B and  C, respectively) . However, at 64 C, samples with more than 20% methylation could not be differentiated from a fully methylated sample. Therefore, real-time MS-HRM at 60 C and 64 C was both conducted to accurately determine the level of hTERT methylation in clinical samples.
Application of the hTERT real-time MS-HRM assay to clinical specimens
hTERT methylation through real-time MS-HRM analysis could provide a useful contribution to the diagnosis of leptomeningeal metastasis, as cytologic examination of these CSF stayed doubtful. The applicability of the hTERT real-time MS-HRM assay was tested on a panel of 77 CSF samples from a total of 67 patients. CSF samples were first processed via a cytologic analysis where they were grouped C for the PCR. C, comparison of hTERT methylation quantification by TaqMan probe when using an annealing temperature of 60 C or 64 C. M, methylated sequences; U, unmethylated sequences. The evaluation of the methylation was calculated as the ratio between methylation part (M) monitored by the Taqman MGB probe and the totality of the PCR amplification (MþU) measured by the SYTO9. The ratio was calculated on the basis of the 2 standard curve relative quantification method. The 1/10 and 1/100 samples represent the dilution ratio of fully methylated DNA.
as negative, positive, or suspicious. Among those 77 CSF samples, 24 were negative controls from patients with nontumor, 12 were positive, and 41 were suspected for leptomeningeal metastasis (Table 1) .
Of the 77 investigated CSFs, the DNA-extracted and bisulfite-modified from 69 (90%) samples were amplifiable by PCR. Eight CSFs were not amplified probably because of the limited number of collected cells. Three of these samples were negative controls and 5 were suspected for leptomeningeal metastasis.
The 21 amplified CSF samples from 21 patients with nonneoplastic diseases, including inflammatory diseases and viral syndromes, were used as negative controls. No hTERT methylation was detected in any of the nonmalignant control CSF samples ( Table 1 ). The specificity was therefore 100%.
The 12 CSF undoubtedly cytologically positive were considered as positive control (Table 2) . Real-time MS-HRM assays detected hTERT methylation in 11 of the 12 cytologically positive samples (Tables 1 and 2 ). The methylation difference between negative CSF in cytology (noncancerous patient) and highly positive CSF in cytology (cancerous patients) was highly significant (P < 0.0001; Fig.  2 ). The sensitivity of the real-time MS-HRM compared with the cytologic gold standard analysis was of 92%, with a positive prospective value of 100% and a negative prospective value of 95%.
The main interest of the hTERT methylation analysis resided in the cases considered as suspicious for leptomeningeal metastasis without cytologic confirmation. CSF were considered as suspicious when the intensity of the atypia and/or when the number of atypical cells were insufficient. Leptomeningeal metastasis was clinically suspected in 34 patients corresponding to 41 CSF samples (Table 3) . To avoid false-positive results due to the possible occurrence of few hTERT-methylated cells in the nontumoral cell population, real-time MS-HRM assay in the corresponding primary tumors was conducted with an annealing temperature of 60 C (Fig. 1A) . If the level of hTERT methylation was under 10%, the primary tumor was CSFs from patients with an hTERT-methylated primary tumor. c CSFs from patients with an hTERT-unmethylated primary tumor. (Table 3 ; patients 23-32) and thus, hTERT methylation could not be used as a cancer marker in the corresponding CSF. Most of these tumors arose from the brain (medulloblastoma, meningioma, and thalamic tumor). As expected, the 10 CSF samples from these 10 patients were found hTERT unmethylated, even if tumor cells were suspected by cytology. As a consequence, these samples were excluded from the different evaluation parameters.
With the elimination of nonamplified CSF samples and of the unmethylated primary tumor, the number of suspicious CSF samples was 26, corresponding to 22 patients (Table 3 ; samples 1-26). Seventeen (65%) out of these 26 CSF suspicious samples were found with hTERT methylated and 9 (35%) were found with hTERT unmethylated by realtime MS-HRM analysis (Tables 1 and 3 ). The accurate identification of cancer cells by cytologic examination might be hampered by the low occurrence of these cells and/or by the morphologic difficulty to distinguish malignant from normal cells in these CSF specimens. Indeed, methylation of 12 (70%) of the 17 hTERT-methylated samples was only detected by the most sensitive approach (real-time MS-HRM at 64 C), which indicates that the percentage of tumor cells harboring an hTERT-methylated promoter is relatively low in these samples, probably between 0.5% and 5%.
Discussion
As hTERT hypermethylation is very common in a majority of cancers contrarily to normal cells (21), we evaluated its efficiency as a potential biomarker in the diagnosis of leptomeningeal metastasis. The specificity and the sensitivity of a new biomarker are 2 crucial parameters for diagnostic purpose. In our series, hTERT methylation was only detected in the CSF from patients with a known malignancy and thus, the specificity was 100%. The sensitivity of 92% is very high and means that the presence of few false-negative cases remains but stays lower than most other markers, such as CA-125 (28). To our knowledge, the use of DNA methylation as a diagnostic tool for leptomeningeal metastasis was never investigated in CSF.
Normal tissues with proliferative somatic cells such as colorectal crypts, gastric, prostate, and endometrial cells, revealed telomerase activity and hTERT expression concomitantly with the presence of hTERT methylation (21) . In most normal tissues, only a hypomethylated hTERT promoter was detected with standard approaches (19) (20) (21) . When a sensitive approach was used, such as the real-time MS-HRM presented in this study, a low level of hTERT methylation (1%-10%) was observed in certain normal tissues such as breast and lung, and occasionally in brain, kidney, placenta, and skin (J. Benhattar, Lausanne University Hospital, Lausanne, Switzerland; Unpublished results). Nevertheless, hTERT methylation was undetectable in the remaining analyzed tissues (amygdale, bladder, heart, liver, muscle, and testis) and in the biologic fluids (blood and CSF). The use of hTERT methylation as a cancer biomarker should be limited to tissues and biologic fluids with undetectable level of hTERT methylation in nontumoral control samples. As shown in this study, the CSF is fully suitable for the application of this biomarker given the fact that hTERT methylation was found undetectable in the 21 nontumoral control CSF samples.
In normal somatic cells, hTERT methylation may randomly occur and at low levels in only one or few CpG sites within the region of interest (29) . Interestingly, in a nontumoral sample, each single cell has its own methylation pattern and thus the methylated CpGs vary from one cell to another. To avoid this background signal, not only a single CpG site but also global analysis of both the entire amplified region (MS-HRM) and multiple CpG sites (real-time TaqMan PCR) was conducted in this study. Sensitive detection was achieved by using PCR primers that contained CpG dinucleotides, which induced a bias toward hTERT-methylated DNA. Using real-time MS-HRM, we were able to detect as low as 1% of hTERT methylation in CFS samples, which could correspond to the detection of 1% of tumor cells in a background of normal cells.
In our series, bisulfite-modified DNA was successfully amplified in 90% of the CSF specimens, which confirms the overall relatively good preservation of DNA in CSF (30) . The sensitivity of the real-time MS-HRM compared with the cytologic gold standard analysis was of 92%. The only cytologically positive sample that was negative for hTERT methylation was the one with the lowest cellular density. Nevertheless, the cytologic analysis identified about 5% atypical cells, which should have been easily detectable by real-time MS-HRM. Sample variation could explain the discrepancy between the cytology and the methylation analysis, like aggregate formation. HTERT-unmethylated metastasizing cells from an hTERT-methylated primary tumor could be another alternative. The possibility of cytologic false-positive diagnosis due to atypical reactive change, especially after intrathecal chemotherapy and/or radiotherapy, should also be considered. Interestingly, in most of the investigated CSF samples found positive by the hTERT methylation test, the level of hTERT methylation correlated relatively well with the percentage of tumor/ atypical cells estimated by cytology.
The simplicity, rapidity, and sensitivity of the real-time MS-HRM procedure in a single-tube assay could be helpful for the diagnosis of leptomeningeal metastasis, especially in the samples where the CSF cytology is doubtful or suspicious. Indeed, in these samples, the confirmation of the presence or absence of leptomeningeal metastasis is hard to obtain. The evidence of leptomeningeal metastasis can be missed in CSF samples taken several weeks later, meningeal biopsies are not done and autopsies are rare and, when conducted, may escape detection of leptomeningeal dissemination. Prognosis of patients with leptomeningeal metastasis is poor and the patients died rapidly. Those patients already have an advanced disease and it is not possible to prove that the death is in direct relation with the leptomeningeal metastasis. The presence of several tumor cells in CSF will not necessarily lead to the beginning of a treatment, it will depend on others factors like the general state of the patient. The potential treatment given to the patient can be effective or not, and can therefore lead to further positive or negative CSF samples for the presence of tumor cells. However, in case of the absence of tumor cells in a given CSF sample, the positivity in further samples doesn't indicate a false-negative result of the first CSF but rather a possible tumor expansion in the CSF. Moreover, we also have to consider that CSF can be taken from a location that is far away from the precise location of the metastasis and do not necessarily reflect the presence of leptomeningeal metastasis or the therapeutic response.
In our series, all but one of the unmethylated hTERT tumors was emerging from brain. Therefore, the research of leptomeningeal metastasis by hTERT methylation detection should probably be restricted to tumors that originate from epithelial cells like breast, lung, prostate, or colon cancers to avoid the absence of marker in the primary tumor. The question remains for the detection in CSF of hTERT methylation in patients with nonepithelial tumors, such as medulloblastoma and lymphoma. In our series, medulloblastoma primary tumors harbored a hypermethylated hTERT promoter in only 2 of the 5 cases investigated. To be more significant, we increased the number of medulloblastoma to 19. Only 7 (37%) tumors revealed an hTERTmethylated promoter confirming the relatively low value of the hTERT methylation detection in medulloblastoma. Nevertheless, in doubtful cytology, a positive hTERT methylation test would indicate a leptomeningeal dissemination that might be of diagnostic interest. The B-cell lymphomas were excluded from this study from the start, even if this kind of tumor highly metastasizes in brain. Indeed, we have previously shown that these lymphoproliferative tumors are rarely hTERT hypermethylated (23) . Furthermore, other sensitive tests, such as clonal B-cell gene rearrangement analysis, are easily available (31, 32) .
In conclusion, hTERT methylation through real-time MS-HRM analysis could provide a useful contribution to the diagnosis of leptomeningeal metastasis, especially in cases where the cytologic interpretation is limited by the low number of tumor cells and/or morphologic cell changes due to treatment. Detection of gene promoter hypermethylation in CSF is a new approach (33) and, according to the data obtained in this study, hTERT methylation represents a valuable adjunct to routine cytology for the accurate diagnosis of leptomeningeal metastasis in a large number of cancer types.
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